English High Court finds Bayer patent obvious in win for Teva

The English High Court has found that a challenged claim of Bayer's targeted cancer drug sorafenib is invalid due to obviousness, in a win for Israeli pharmaceutical company Teva Pharmaceuticals.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Plant Varieties

Rival sues Monsanto, Bayer over GM plant tech

11 August 2022 Firms accused of using GM tech for herbicide-resistant plants | Plaintiff says its patented tech helps farmers to innovate | US District Court for the District of Delaware.

Americas

Biogen sues Teva over MS generic

18 March 2021 A proposed Teva Pharmaceutical generic drug to treat multiple sclerosis infringes patents relating to Vumerity, according to a lawsuit filed by Biogen and Alkermes.

Americas

Fed Circ panel reviews $235m GSK award over ‘skinny’ Teva generic

25 February 2021 A panel of the US Court of Appeals for the Federal Circuit has considered for a second time the $235 million award to GlaxoSmithKline after Teva Pharmaceuticals was found to have infringed its Coreg heart drug.

More features

Ropes & Gray loses 21-attorney group to join rival on growth spree

How 'Boehringer' sets preliminary relief threshold for generics

The Quintara decision: Defining trade secrets in federal cases

To disclose or not: Pharma patents face new AI reality

Trade secrets go global: How brand owners face a high-stakes battlefront

Killing the golden goose of US drug innovation (Part II): Drug pricing myths

Former pharma GC brings in-house perspective to McGuireWoods

Sandoz eyes US biosimilar launch as Regeneron settles

English High Court finds Bayer patent obvious in win for Teva

More on this story

Editor's picks

Editor's picks

More features